Loading…

Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species

Pharmacokinetic-pharmacodynamic (PK/PD) targets of vancomycin therapy have been recognized for methicillin-resistant Staphylococcus aureus infections but not for other gram-positive bacterial infections. Therefore, we investigated whether vancomycin concentration targets such as the trough level and...

Full description

Saved in:
Bibliographic Details
Published in:BMC Infectious Diseases 2021, Vol.21 (1)
Main Authors: Sohn, Yujin, Rim, John Hoon, Cho, Yunsuk, Hyun, Jonghoon, Baek, Yaejee, Kim, Moohyun, Kim, Jung Ho, Seong, Hye, Ahn, Jin Young, Lee, Sang-Guk, Lim, Jong-Beack, Jeong, Su Jin, Ku, Nam Su, Choi, Jun Yong, Yeom, Joon-Sup, Song, Young Goo
Format: Report
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1
container_start_page
container_title BMC Infectious Diseases
container_volume 21
creator Sohn, Yujin
Rim, John Hoon
Cho, Yunsuk
Hyun, Jonghoon
Baek, Yaejee
Kim, Moohyun
Kim, Jung Ho
Seong, Hye
Ahn, Jin Young
Lee, Sang-Guk
Lim, Jong-Beack
Jeong, Su Jin
Ku, Nam Su
Choi, Jun Yong
Yeom, Joon-Sup
Song, Young Goo
description Pharmacokinetic-pharmacodynamic (PK/PD) targets of vancomycin therapy have been recognized for methicillin-resistant Staphylococcus aureus infections but not for other gram-positive bacterial infections. Therefore, we investigated whether vancomycin concentration targets such as the trough level and ratio of the area under the curve to minimum inhibitory concentration (AUC/MIC) are associated with the treatment outcome in enterococcal bacteremia. A retrospective cohort analysis enrolled patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis who were treated with vancomycin from January 2007 to December 2017 at a tertiary hospital located in Seoul, South Korea. Patients without vancomycin concentrations were excluded from the study. The primary outcome was 28-day all-cause mortality. A total of 37 patients were enrolled--26 with E. faecium infection and 11 with E. faecalis infection. The 28-day all-cause mortality rate was 21.6 %. In univariate analysis, vancomycin trough level ([less than or equai to] 15 [micro]g/mL; p = 0.042), age (p = 0.044), and septic shock (p = 0.049) were associated with 28-day mortality but not AUC24/MIC (> 389; p = 0.479). In multivariate analysis, vancomycin trough concentration ([less than or equai to] 15 [micro]g/mL; p = 0.041) and younger age (p = 0.031) were associated with 28-day mortality in patients with enterococcal bacteremia. In this study, a vancomycin trough level of 15 [micro]g/mL or lower was associated with 28-day mortality in enterococcal bacteremia. However, relatively large prospective studies are needed to examine the efficacy of vancomycin PK/PD parameters in patients with enterococcal bacteremia.
doi_str_mv 10.1186/s12879-021-06809-x
format report
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A681643532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A681643532</galeid><sourcerecordid>A681643532</sourcerecordid><originalsourceid>FETCH-gale_infotracmisc_A6816435323</originalsourceid><addsrcrecordid>eNqNjbtOAzEQRS0EEuHxA1QjURv8WPZRRiiID0gfOcNs1ijriXa8QFq-HCOloKS6ozPn6ip1Z82DtW39KNa1TaeNs9rUren015la2Kqx2nlfnf-5L9WVyLsxtmldt1DfSxHGGHLkBNzDR0jI4xFjgjzxvBsAOSGlPJ2UwgcqPwp5LBh4zqVAv91DUQoS-Ix5gG3ATBONMQCGWegNtkdYpcIYGXEWkANhJLlRF33YC92e8lrdv6zWz696F_a0iannMo5jFNws69bWlX_yzv_P-gErmVl7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Sohn, Yujin ; Rim, John Hoon ; Cho, Yunsuk ; Hyun, Jonghoon ; Baek, Yaejee ; Kim, Moohyun ; Kim, Jung Ho ; Seong, Hye ; Ahn, Jin Young ; Lee, Sang-Guk ; Lim, Jong-Beack ; Jeong, Su Jin ; Ku, Nam Su ; Choi, Jun Yong ; Yeom, Joon-Sup ; Song, Young Goo</creator><creatorcontrib>Sohn, Yujin ; Rim, John Hoon ; Cho, Yunsuk ; Hyun, Jonghoon ; Baek, Yaejee ; Kim, Moohyun ; Kim, Jung Ho ; Seong, Hye ; Ahn, Jin Young ; Lee, Sang-Guk ; Lim, Jong-Beack ; Jeong, Su Jin ; Ku, Nam Su ; Choi, Jun Yong ; Yeom, Joon-Sup ; Song, Young Goo</creatorcontrib><description>Pharmacokinetic-pharmacodynamic (PK/PD) targets of vancomycin therapy have been recognized for methicillin-resistant Staphylococcus aureus infections but not for other gram-positive bacterial infections. Therefore, we investigated whether vancomycin concentration targets such as the trough level and ratio of the area under the curve to minimum inhibitory concentration (AUC/MIC) are associated with the treatment outcome in enterococcal bacteremia. A retrospective cohort analysis enrolled patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis who were treated with vancomycin from January 2007 to December 2017 at a tertiary hospital located in Seoul, South Korea. Patients without vancomycin concentrations were excluded from the study. The primary outcome was 28-day all-cause mortality. A total of 37 patients were enrolled--26 with E. faecium infection and 11 with E. faecalis infection. The 28-day all-cause mortality rate was 21.6 %. In univariate analysis, vancomycin trough level ([less than or equai to] 15 [micro]g/mL; p = 0.042), age (p = 0.044), and septic shock (p = 0.049) were associated with 28-day mortality but not AUC24/MIC (&gt; 389; p = 0.479). In multivariate analysis, vancomycin trough concentration ([less than or equai to] 15 [micro]g/mL; p = 0.041) and younger age (p = 0.031) were associated with 28-day mortality in patients with enterococcal bacteremia. In this study, a vancomycin trough level of 15 [micro]g/mL or lower was associated with 28-day mortality in enterococcal bacteremia. However, relatively large prospective studies are needed to examine the efficacy of vancomycin PK/PD parameters in patients with enterococcal bacteremia.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-021-06809-x</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Bacteremia ; Care and treatment ; Diagnosis ; Dosage and administration ; Methods ; Pharmacokinetics ; Prevention ; Risk factors ; Staphylococcus aureus infections ; Vancomycin</subject><ispartof>BMC Infectious Diseases, 2021, Vol.21 (1)</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,4476,27902</link.rule.ids></links><search><creatorcontrib>Sohn, Yujin</creatorcontrib><creatorcontrib>Rim, John Hoon</creatorcontrib><creatorcontrib>Cho, Yunsuk</creatorcontrib><creatorcontrib>Hyun, Jonghoon</creatorcontrib><creatorcontrib>Baek, Yaejee</creatorcontrib><creatorcontrib>Kim, Moohyun</creatorcontrib><creatorcontrib>Kim, Jung Ho</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Ahn, Jin Young</creatorcontrib><creatorcontrib>Lee, Sang-Guk</creatorcontrib><creatorcontrib>Lim, Jong-Beack</creatorcontrib><creatorcontrib>Jeong, Su Jin</creatorcontrib><creatorcontrib>Ku, Nam Su</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><creatorcontrib>Yeom, Joon-Sup</creatorcontrib><creatorcontrib>Song, Young Goo</creatorcontrib><title>Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species</title><title>BMC Infectious Diseases</title><description>Pharmacokinetic-pharmacodynamic (PK/PD) targets of vancomycin therapy have been recognized for methicillin-resistant Staphylococcus aureus infections but not for other gram-positive bacterial infections. Therefore, we investigated whether vancomycin concentration targets such as the trough level and ratio of the area under the curve to minimum inhibitory concentration (AUC/MIC) are associated with the treatment outcome in enterococcal bacteremia. A retrospective cohort analysis enrolled patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis who were treated with vancomycin from January 2007 to December 2017 at a tertiary hospital located in Seoul, South Korea. Patients without vancomycin concentrations were excluded from the study. The primary outcome was 28-day all-cause mortality. A total of 37 patients were enrolled--26 with E. faecium infection and 11 with E. faecalis infection. The 28-day all-cause mortality rate was 21.6 %. In univariate analysis, vancomycin trough level ([less than or equai to] 15 [micro]g/mL; p = 0.042), age (p = 0.044), and septic shock (p = 0.049) were associated with 28-day mortality but not AUC24/MIC (&gt; 389; p = 0.479). In multivariate analysis, vancomycin trough concentration ([less than or equai to] 15 [micro]g/mL; p = 0.041) and younger age (p = 0.031) were associated with 28-day mortality in patients with enterococcal bacteremia. In this study, a vancomycin trough level of 15 [micro]g/mL or lower was associated with 28-day mortality in enterococcal bacteremia. However, relatively large prospective studies are needed to examine the efficacy of vancomycin PK/PD parameters in patients with enterococcal bacteremia.</description><subject>Bacteremia</subject><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Methods</subject><subject>Pharmacokinetics</subject><subject>Prevention</subject><subject>Risk factors</subject><subject>Staphylococcus aureus infections</subject><subject>Vancomycin</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2021</creationdate><recordtype>report</recordtype><sourceid/><recordid>eNqNjbtOAzEQRS0EEuHxA1QjURv8WPZRRiiID0gfOcNs1ijriXa8QFq-HCOloKS6ozPn6ip1Z82DtW39KNa1TaeNs9rUren015la2Kqx2nlfnf-5L9WVyLsxtmldt1DfSxHGGHLkBNzDR0jI4xFjgjzxvBsAOSGlPJ2UwgcqPwp5LBh4zqVAv91DUQoS-Ix5gG3ATBONMQCGWegNtkdYpcIYGXEWkANhJLlRF33YC92e8lrdv6zWz696F_a0iannMo5jFNws69bWlX_yzv_P-gErmVl7</recordid><startdate>20211026</startdate><enddate>20211026</enddate><creator>Sohn, Yujin</creator><creator>Rim, John Hoon</creator><creator>Cho, Yunsuk</creator><creator>Hyun, Jonghoon</creator><creator>Baek, Yaejee</creator><creator>Kim, Moohyun</creator><creator>Kim, Jung Ho</creator><creator>Seong, Hye</creator><creator>Ahn, Jin Young</creator><creator>Lee, Sang-Guk</creator><creator>Lim, Jong-Beack</creator><creator>Jeong, Su Jin</creator><creator>Ku, Nam Su</creator><creator>Choi, Jun Yong</creator><creator>Yeom, Joon-Sup</creator><creator>Song, Young Goo</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20211026</creationdate><title>Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species</title><author>Sohn, Yujin ; Rim, John Hoon ; Cho, Yunsuk ; Hyun, Jonghoon ; Baek, Yaejee ; Kim, Moohyun ; Kim, Jung Ho ; Seong, Hye ; Ahn, Jin Young ; Lee, Sang-Guk ; Lim, Jong-Beack ; Jeong, Su Jin ; Ku, Nam Su ; Choi, Jun Yong ; Yeom, Joon-Sup ; Song, Young Goo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_infotracmisc_A6816435323</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bacteremia</topic><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Methods</topic><topic>Pharmacokinetics</topic><topic>Prevention</topic><topic>Risk factors</topic><topic>Staphylococcus aureus infections</topic><topic>Vancomycin</topic><toplevel>online_resources</toplevel><creatorcontrib>Sohn, Yujin</creatorcontrib><creatorcontrib>Rim, John Hoon</creatorcontrib><creatorcontrib>Cho, Yunsuk</creatorcontrib><creatorcontrib>Hyun, Jonghoon</creatorcontrib><creatorcontrib>Baek, Yaejee</creatorcontrib><creatorcontrib>Kim, Moohyun</creatorcontrib><creatorcontrib>Kim, Jung Ho</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Ahn, Jin Young</creatorcontrib><creatorcontrib>Lee, Sang-Guk</creatorcontrib><creatorcontrib>Lim, Jong-Beack</creatorcontrib><creatorcontrib>Jeong, Su Jin</creatorcontrib><creatorcontrib>Ku, Nam Su</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><creatorcontrib>Yeom, Joon-Sup</creatorcontrib><creatorcontrib>Song, Young Goo</creatorcontrib></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sohn, Yujin</au><au>Rim, John Hoon</au><au>Cho, Yunsuk</au><au>Hyun, Jonghoon</au><au>Baek, Yaejee</au><au>Kim, Moohyun</au><au>Kim, Jung Ho</au><au>Seong, Hye</au><au>Ahn, Jin Young</au><au>Lee, Sang-Guk</au><au>Lim, Jong-Beack</au><au>Jeong, Su Jin</au><au>Ku, Nam Su</au><au>Choi, Jun Yong</au><au>Yeom, Joon-Sup</au><au>Song, Young Goo</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species</atitle><jtitle>BMC Infectious Diseases</jtitle><date>2021-10-26</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Pharmacokinetic-pharmacodynamic (PK/PD) targets of vancomycin therapy have been recognized for methicillin-resistant Staphylococcus aureus infections but not for other gram-positive bacterial infections. Therefore, we investigated whether vancomycin concentration targets such as the trough level and ratio of the area under the curve to minimum inhibitory concentration (AUC/MIC) are associated with the treatment outcome in enterococcal bacteremia. A retrospective cohort analysis enrolled patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis who were treated with vancomycin from January 2007 to December 2017 at a tertiary hospital located in Seoul, South Korea. Patients without vancomycin concentrations were excluded from the study. The primary outcome was 28-day all-cause mortality. A total of 37 patients were enrolled--26 with E. faecium infection and 11 with E. faecalis infection. The 28-day all-cause mortality rate was 21.6 %. In univariate analysis, vancomycin trough level ([less than or equai to] 15 [micro]g/mL; p = 0.042), age (p = 0.044), and septic shock (p = 0.049) were associated with 28-day mortality but not AUC24/MIC (&gt; 389; p = 0.479). In multivariate analysis, vancomycin trough concentration ([less than or equai to] 15 [micro]g/mL; p = 0.041) and younger age (p = 0.031) were associated with 28-day mortality in patients with enterococcal bacteremia. In this study, a vancomycin trough level of 15 [micro]g/mL or lower was associated with 28-day mortality in enterococcal bacteremia. However, relatively large prospective studies are needed to examine the efficacy of vancomycin PK/PD parameters in patients with enterococcal bacteremia.</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s12879-021-06809-x</doi></addata></record>
fulltext fulltext
identifier ISSN: 1471-2334
ispartof BMC Infectious Diseases, 2021, Vol.21 (1)
issn 1471-2334
1471-2334
language eng
recordid cdi_gale_infotracmisc_A681643532
source PubMed (Medline); Publicly Available Content Database
subjects Bacteremia
Care and treatment
Diagnosis
Dosage and administration
Methods
Pharmacokinetics
Prevention
Risk factors
Staphylococcus aureus infections
Vancomycin
title Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T21%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Association%20of%20vancomycin%20trough%20concentration%20on%20the%20treatment%20outcome%20of%20patients%20with%20bacteremia%20caused%20by%20Enterococcus%20species&rft.jtitle=BMC%20Infectious%20Diseases&rft.au=Sohn,%20Yujin&rft.date=2021-10-26&rft.volume=21&rft.issue=1&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-021-06809-x&rft_dat=%3Cgale%3EA681643532%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-gale_infotracmisc_A6816435323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A681643532&rfr_iscdi=true